BCMA bispecific

Phase 2

CCase Comprehensive Cancer Center

BCMA bispecific is one of 5 therapeutic programs targeting Amyloid. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

AmyloidNot yet recruiting

AmyloidPhase 2

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Amyloid

#DrugCompanyPhaseTrials

Kisunla

Eli Lilly

Approved

1 2

Tecvayli

Johnson & Johnson

Phase 2

1 3

DARZALEX FASPRO

Johnson & Johnson

Phase 2

1 4

Amyvid

IInvicro

Phase 2

2 5

BCMA bispecific

CCase Comprehensive Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 2Not yet recruiting

Amyloid

NCT07524634

Clinical

Trials by Indication[1]

Amyloid1 trial

Dose Schedule Investigation of B-Cell Maturation Antigen (BCMA) Bispecific Antibody, Elranatamab, for Treatment of Newly Diagnosed Light Chain Amyloidosis

Not yet recruiting·CCase Comprehensive Cancer Center·Phase 2·NCT07524634·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BCMA bispecific. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for BCMA bispecific. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Case Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCase Comprehensive Cancer Center

BCMA bispecific

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Amyloid1 trial

References

Drug Info

Quick Facts

Related News